NeoGenomics, Inc. (NEO) DCF Valuation
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
NeoGenomics, Inc. (NEO) Bundle
Gain insight into your NeoGenomics, Inc. (NEO) valuation analysis with our sophisticated DCF Calculator! Preloaded with real NEO data, this Excel template enables you to adjust forecasts and assumptions for an accurate calculation of NeoGenomics' intrinsic value.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 408.8 | 444.4 | 484.3 | 509.7 | 591.6 | 649.3 | 712.6 | 782.1 | 858.4 | 942.1 |
| Revenue Growth, % | 0 | 8.71 | 8.97 | 5.24 | 16.07 | 9.75 | 9.75 | 9.75 | 9.75 | 9.75 |
| EBITDA | 43.3 | 34.9 | 52.1 | -78.6 | -17.6 | 14.0 | 15.4 | 16.9 | 18.5 | 20.3 |
| EBITDA, % | 10.58 | 7.84 | 10.75 | -15.43 | -2.98 | 2.15 | 2.15 | 2.15 | 2.15 | 2.15 |
| Depreciation | 35.9 | 41.9 | 62.1 | 79.2 | 72.6 | 76.4 | 83.8 | 92.0 | 101.0 | 110.8 |
| Depreciation, % | 8.78 | 9.42 | 12.82 | 15.54 | 12.27 | 11.77 | 11.77 | 11.77 | 11.77 | 11.77 |
| EBIT | 7.4 | -7.0 | -10.0 | -157.8 | -90.2 | -62.4 | -68.5 | -75.2 | -82.5 | -90.5 |
| EBIT, % | 1.8 | -1.58 | -2.06 | -30.96 | -15.24 | -9.61 | -9.61 | -9.61 | -9.61 | -9.61 |
| Total Cash | 173.0 | 296.3 | 515.4 | 438.0 | 415.2 | 474.1 | 520.3 | 571.1 | 626.8 | 687.9 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 94.2 | 106.8 | 112.1 | 119.7 | 131.2 | 150.5 | 165.2 | 181.3 | 199.0 | 218.4 |
| Account Receivables, % | 23.05 | 24.04 | 23.15 | 23.49 | 22.18 | 23.18 | 23.18 | 23.18 | 23.18 | 23.18 |
| Inventories | 14.4 | 29.5 | 23.4 | 24.3 | 24.2 | 31.0 | 34.0 | 37.3 | 40.9 | 44.9 |
| Inventories, % | 3.52 | 6.64 | 4.83 | 4.76 | 4.08 | 4.77 | 4.77 | 4.77 | 4.77 | 4.77 |
| Accounts Payable | 19.6 | 25.0 | 17.9 | 20.5 | 20.3 | 28.0 | 30.7 | 33.7 | 37.0 | 40.6 |
| Accounts Payable, % | 4.79 | 5.62 | 3.7 | 4.02 | 3.44 | 4.31 | 4.31 | 4.31 | 4.31 | 4.31 |
| Capital Expenditure | -20.0 | -29.1 | -64.1 | -30.9 | -28.8 | -46.2 | -50.8 | -55.7 | -61.1 | -67.1 |
| Capital Expenditure, % | -4.9 | -6.55 | -13.24 | -6.06 | -4.86 | -7.12 | -7.12 | -7.12 | -7.12 | -7.12 |
| Tax Rate, % | 9.4 | 9.4 | 9.4 | 9.4 | 9.4 | 9.4 | 9.4 | 9.4 | 9.4 | 9.4 |
| EBITAT | 16.2 | 2.1 | -5.5 | -142.9 | -81.7 | -42.0 | -46.1 | -50.6 | -55.5 | -60.9 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -57.0 | -7.4 | -13.8 | -100.4 | -49.5 | -30.3 | -28.0 | -30.7 | -33.7 | -37.0 |
| WACC, % | 8.78 | 7.78 | 8.33 | 8.69 | 8.69 | 8.45 | 8.45 | 8.45 | 8.45 | 8.45 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -124.7 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -38 | |||||||||
| Terminal Value | -584 | |||||||||
| Present Terminal Value | -389 | |||||||||
| Enterprise Value | -514 | |||||||||
| Net Debt | 269 | |||||||||
| Equity Value | -783 | |||||||||
| Diluted Shares Outstanding, MM | 126 | |||||||||
| Equity Value Per Share | -6.24 |
What You Will Get
- Real NeoGenomics Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures.
- Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on NeoGenomics’ fair value.
- Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections.
- Time-Saving and Accurate: Skip building models from scratch while maintaining precision and flexibility.
Key Features
- Comprehensive NEO Data: Pre-filled with NeoGenomics’ historical financials and future projections.
- Customizable Assumptions: Modify revenue growth rates, profit margins, discount rates, tax liabilities, and capital investments.
- Interactive Valuation Tool: Automatic recalculations of Net Present Value (NPV) and intrinsic value based on your adjustments.
- Scenario Analysis: Develop various forecasting scenarios to evaluate different valuation possibilities.
- Intuitive Interface: Designed for ease of use, catering to both experienced professionals and newcomers.
How It Works
- Download: Obtain the pre-built Excel file containing NeoGenomics' financial data.
- Customize: Modify projections, such as revenue growth, EBITDA %, and WACC.
- Update Automatically: The intrinsic value and NPV calculations refresh in real-time.
- Test Scenarios: Generate multiple forecasts and instantly compare results.
- Make Decisions: Utilize the valuation findings to inform your investment strategy.
Why Choose This Calculator for NeoGenomics, Inc. (NEO)?
- User-Friendly Interface: Perfectly crafted for both novices and seasoned professionals.
- Customizable Inputs: Adjust parameters easily to suit your analytical needs.
- Real-Time Updates: Observe immediate changes in NeoGenomics’ valuation as you modify inputs.
- Preloaded Data: Comes equipped with NeoGenomics’ actual financial information for swift evaluations.
- Relied Upon by Experts: Favored by investors and analysts for making well-informed decisions.
Who Should Use This Product?
- Healthcare Investors: Construct comprehensive valuation models for analyzing NeoGenomics, Inc. (NEO) stock.
- Biotech Finance Teams: Evaluate valuation scenarios to inform strategic decisions within the organization.
- Consultants and Advisors: Deliver precise valuation insights for clients interested in NeoGenomics, Inc. (NEO).
- Students and Educators: Utilize real-world data to enhance learning and practice in financial modeling.
- Life Sciences Enthusiasts: Gain insights into how biotech companies like NeoGenomics, Inc. (NEO) are valued in the market.
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled NeoGenomics historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for NeoGenomics, Inc. (NEO).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.